Alto Neuroscience (NYSE:ANRO) Trading Up 8% Following Earnings Beat

Alto Neuroscience, Inc. (NYSE:ANRO) shares traded up 8% during trading on Thursday following a better than expected earnings announcement. The company traded as high as $31.83 and last traded at $31.5170. Approximately 91,789 shares were traded during mid-day trading, a decline of 75% from the average session volume of 363,648 shares. The stock had previously closed at $29.18.

The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ANRO. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Bank of America started coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Finally, Chardan Capital restated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, April 22nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.62.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter valued at approximately $52,000. Torren Management LLC acquired a new stake in shares of Alto Neuroscience during the fourth quarter worth approximately $62,000. Invesco Ltd. acquired a new stake in shares of Alto Neuroscience during the first quarter worth approximately $67,000. Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Alto Neuroscience during the 4th quarter valued at $198,000.

Alto Neuroscience Stock Performance

The company’s fifty day simple moving average is $25.44 and its two-hundred day simple moving average is $22.57. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -13.24 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.